APOCARE Pharma GmbH APOCARE Pharma GmbH
Research and Development

In recent years the antibiotic resistance of bacteria has become a problem in medicine worldwide. The spectrum of infectious diseases increases rapidly and we are face to a grave situation due to the generation of new mutants of many bacteria strains.

To gain control of this problem new forms of therapy have to be developed to substitute conventional treatments. One attractive approach is the Photodynamic Inactivation (PDI) according to the Photodynamic Therapy (PDT) already used successfully in cancer therapy.

Our aim is to find alternative treatments for scores of infectious diseases. One strategy that can be used to overcome deficiencies of antibiotics and other chemotherapies might be the Photodynamic Inactivation of these microorganisms by our agent Fotolon®.

Thereby we focussed our attention to mycobacterial diseases motivated by the increasing number of Tuberculosis and Leprosy cases. To optimize PDI our research is focussed on the pharmacokinetic, light- and drug application, detection and alternative light sources and qualities (LEDs etc.).

 

We’ll keep you up to date.

  • Contact | 
  • APOCARE Pharma GmbH 33647 Bielefeld, Hauptstrasse 198